Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
6.51(c) 6.42(c) 6.42(c) 6.545(c) 6.64 Last
765 993 1 056 041 593 009 1 063 470 229 855 Volume
-0.91% -1.38% 0.00% +1.95% +1.45% Change
More quotes
Financials ($)
Sales 2017 125 M
EBIT 2017 -64,3 M
Net income 2017 -68,0 M
Debt 2017 -
Yield 2017 -
Sales 2018 130 M
EBIT 2018 -45,1 M
Net income 2018 -47,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 4,19x
Capi. / Sales2018 4,03x
Capitalization 525 M
More Financials
Company
Spectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products.It targets non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma.It operates through... 
More about the company
Surperformance© ratings of Spectrum Pharmaceuticals,
Trading Rating : Investor Rating :
More Ratings
Latest news on SPECTRUM PHARMACEUTICALS,
03/14 SPECTRUM PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
03/10 SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8..
03/08 SPECTRUM PHARMACEUTICALS : Pharma reports 4Q loss
03/08 SPECTRUM PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
03/08 SPECTRUM PHARMACEUTICALS : Reports Fourth Quarter 2016 and Full Year 2016 Financ..
03/01 SPECTRUM PHARMACEUTICALS : Announces Fourth Quarter and Full Year 2016 Financial..
02/16 SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the 2017 RBC Capital M..
01/09 SPECTRUM PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements an..
2016 SPECTRUM PHARMACEUTICALS : Research Reports Initiation on Biotech Stocks -- Incy..
2016 SPECTRUM PHARMACEUTICALS : Highlights Promising Preclinical Data Evaluating Pozi..
More news
Sector news : Biotechnology & Medical Research - NEC
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
03/13Spectrum Pharmaceuticals given $10.00 PT by HC Wainwright. buy rating.  
03/13Spectrum Pharmaceuticals given $11.00 PT by FBR & Co. buy rating.  
03/12$SPPI "I was basing it on the total market" on ADFN InvestorsHub message boar.. 
03/10$SPPI board awarded CEO Raj Shrotriya a $945,000 bonus for 2016. Stock fell 2..
4
03/10Spectrum Pharmaceuticals, Inc. $SPPI Releases Earnings Results, Beats Estimat.. 
More tweets
Qtime:21
News from SeekingAlpha
03/09 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
03/08 Spectrum Pharmaceuticals' (SPPI) CEO Rajesh Shrotriya on Q4 2016 Results - Ea..
03/08 After Hours Gainers / Losers
03/08 Spectrum Pharma Q4 top line down 30%, net loss widens; shares down 15% after ..
03/08 Spectrum Pharmaceuticals beats by $0.03, beats on revenue
Advertisement
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Full-screen chart
Technical analysis trends SPECTRUM PHARMACE...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 9,63 $
Spread / Average Target 47%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Rajesh C. Shrotriya Chairman & Chief Executive Officer
Joseph W. Turgeon President & Chief Operating Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Stuart Mitchell Krassner Independent Non-Employee Director
Luigi Lenaz Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SPECTRUM PHARMACEUTICA..47.74%525
INCYTE CORPORATION38.60%28 325
QUINTILES IMS HOLDINGS..1.87%18 277
LONZA GROUP AG2.72%10 645
CELLTRION, INC.--.--%9 610
SEATTLE GENETICS, INC.19.80%9 008
More Results